Answers are grounded in this paper and cite their sources.
Soluble antigen-based cancer vaccines have poor retention in tissues along with suboptimal antigen processing by dendritic cells. Multiple booster doses are often needed, leading to dose-limiting systemic toxicity. A versatile, immunomodulatory, self-assembly protein nanogel vaccine is reported that induces robust immune cell response at lower antigen doses than soluble antigens, an important step towards biomaterials-based safer immunotherapy approaches.
No takes yet. Share an insight, caveat, or question.
Purwada et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: